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1. INTRODUCTION 
Hypoglycemic sulfonylureas provoke insulin 
release apparently by stimulating the inflow of 
Ca*+ into pancreatic islet cells [ 1,2]. The 
mechanism by which hypoglycemic sulfonylureas 
facilitate Ca*+ inflow into the B cell is not 
elucidated. It is conceivable but remains to be pro- 
ved that such a facilitation is somehow related to 
the ionophoretic capacity of hypoglycemic 
sulfonylureas [3]. These agents are able to trans- 
locate Ca*+ into or across a hydrophobic domain 
[4]. Hypoglycemic sulfonylureas act synergistically 
with the ionophore A23187 [5], and possibly native 
ionophores [6], a situation attributable to the for- 
mation of a hybrid complex in which each Ca*+ ion 
is bound to both one molecule of A23187 and one 
molecule of the hypoglycemic agent [7]. 
was purchased from Sigma (St Louis, MO). 
Praseodymium chloride (PrCls .6HzO) was obtain- 
ed from Aldrich (Beerse). Glibenclamide and gli- 
clazide were kindly provided by Hoechst Belgium 
and Servier Benelux (Brussels), respectively. 
Several studies have shown that ‘H-NMR can be 
used to measure the transport of paramagnetic 
ions, as a model for Ca*+ transport, across 
phospholipid membranes [g-13]. Thus, in the 
absence of ionophore, the paramagnetic ion Pr3+ 
shifts the trimethylammonium proton signal on the 
sole external surface of phosphatidylcholine lipo- 
somes, without penetrating into the liposomal 
lumen [8,11,13]. This study indicates that hypo- 
glycemic sulfonylureas act as Pr3+-ionophore in 
liposomes. 
2. MATERIALS AND METHODS 
DL-a-dipalmitoyl-phosphatidylcholine (DPPC) 
Monolamellar and oligolamellar lipid vesicles 
were prepared by sonicating 100 mg of DPPC 
(Ctimes for 3 min) in 4 ml of D20 (99.8%; Merck, 
Darmstadt). The solution contained NaOH 
(10 PM) to minimize the lowering of pH upon ad- 
dition of PrCls. Under these conditions, the inter- 
nal and external pH averaged 9.0 + 0.1 and 7.4 f 
0.1, respectively, after addition of PrCl3. We used 
a Branson sonifier (type B12) fitted with a normal 
tip at 65 W. Glibenclamide or gliclazide were add- 
ed to the liposomal suspension from either a stock 
solution in dimethylsulfoxide (final concentration 
of the solvent < 1%) v/v) or a dry film prepared 
in the NMR tubes by evaporation of the solvent 
(chloroform) under a stream of N2 [13]. The two 
procedures yielded essentially the same results. The 
nominal concentration of sulfonylurea ranged 
from 0.6 to 2.0 mM (when expressed relative to the 
volume of the liposomal suspension) or 1.8 to 
6.0 mol/lOO mol of lipid (when expressed relative 
to the amount of DPPC present in each sample). 
When examining the influence of hypoglycemic 
sulfonylureas upon Pr3+ transport, the drugs were 
added to the liposomal suspension a few min prior 
to the addition of PrC13. The hypoglycemic agents 
failed to affect the NMR spectra in the absence of 
PrCI3. In all experiments, PrCl3 (10~1, 300 mM) 
was added to yield an initial extravesicular con- 
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centration close to 6 mM. 
The NMR spectra were recorded at 60°C in a 
Jeol X 100 spectrometer at 100 MHz in 5-mm 
NMR tubes containing 0.5 ml of the liposomal 
suspension. The rate of Pr3+ transport was judged 
from either the shift in frequency (expressed in Hz) 
of the intravesicular toward extravesicular head 
group signals or the increase in the extra- 
vesicular/intravesicular ratio for the height of the 
head group signals (expressed as 070 increase 
relative to the initial value). 
3. RESULTS 
Fig.1 illustrates the NMR spectra of DPPC 
liposomes in the absence and presence of PrCl3. 
The spectrum recorded after addition of PrCl3 re- 
mained unchanged for at least 2 h in the absence of 
sulfonylurea, indicating stability of the liposomal 
preparation. The extravesicular/intravesicular 
ratio for the height of head group signals was close 
to 1.5, which would correspond to a mean 
liposomal diameter close to 30 nm in a homo- 
geneous population of unilamellar liposomes 
[11,13]. 
Fig.2 illustrates the changes in the NMR spectra 
of liposomes incubated with hypoglycemic 
sulfonylureas in the presence of PrC13. The rate of 
Pr3+ transport into the vesicles was not vastly dif- 
ferent whether judged from the shift in frequency 
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Fig.1. ‘H-NMR spectrum of DPPC vesicles prior to 
(upper trace) and after (lower trace) addition of PrCl3. 
Chemical shifts are shown in Hz with reference to HzO. 
or increase in the height ratio of the head group 
signals. Thus, in a series of 19 individual deter- 
minations, the regression line relating the shift in 
frequency (S, expressed as Hz) to the increase in 
height ratio (H, expressed as 070) corresponded to 
the following equation: 
S = 0.212 H - 0.004 
with a coefficient of correlation between the two 
measurements amounting to 0.958. The shift in 
frequency was used in the further analysis of ex- 
perimental results. 
Fig.3 (left panel) illustrates the time course for 
the accumulation of Pr3+ in the vesicle lumen as 
judged from the shift in frequency. The mean rate 
of Pr3+ transport, as judged from the 3 first 
readings in each experiment averaged 0.260 f 
0.021 and 1.040 f 0.159 Hz/min in the presence of 
gliclazide 3 and 6 mol/lOO mol of lipid, respective- 
ly, and 0.453 + 0.024 and 1.492 + 0.151 Hz/min 
in the presence of glibenclamide 1.8 and 
6 mol/lOO mol of lipid, respectively. On a molar 
basis, glibenclamide thus appeared more efficient 
than gliclazide in mediating Pr3+ transport. The 
rate of Pr3+ transport was proportional to the drug 
concentration in the presence of glibenclamide 
(fig.3, right panel). In the presence of gliclazide, 
however, the rate of Pr3+ transport relative to the 
concentration of sulfonylurea (mol/lOO mol of 
lipid) increased from 87 -t 7 to 173 + 27 mHz/min 
Fig.2. Changes in ‘H-NMR spectra of head group 
signals from DPPC vesicles incubated in the presence of 
either gliclazide (6 mol/lOO mol of lipid; upper traces) or 
glibenclamide (1.8 mol/lOO mol of lipid; lower traces), 
together with PrClJ. Readings were performed 3, 7, 12 
and 19 min (upper traces), or 3, 7, 14 and 27 min (lower 
traces) after the first reading (left traces), recorded 
shortly (< 2 min) after addition of PrCl3 to the 
liposomal suspension. 
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Fig.3. Time course (left) and dose-action relationship 
(right) for the effect of glibenclamide (triangles) and gli- 
clazide (circles) upon the shift in head group signals in 
DPPC liposomes exposed to PrClr. The shift in 
frequency (left panel) was measured at 2 concentrations 
of each drug (see right panel), the regression line being 
derived from the first 2 (closed symbols) or 3 (open 
symbols) measurements performed after the initial 
reading (time zero). In the right panel, mean values 
(+ SEM) for the shift rate are derived from the first 3 
measurements performed after the initial reading. 
(P < 0.05) as the concentration of the drug was 
raised from 3 to 6 mol/lOO mol of lipid. 
4. DISCUSSION 
The present results demonstrate that two distinct 
hypoglycemic sulfonylureas are able to transport 
Pr3+ across the phospholipid boundary of lipo- 
somes. This is consistent with a preliminary report 
indicating that gliclazide facilitates the release of 
4’Ca from liposomes [14]. 
The rate of Pr3+ transport relative to the molar 
concentration of the drug was one to two orders of 
magnitude lower with glibenclamide than with 
l,l, 1,2,2,3,3-heptafluoro-7,7-dimethyl- 
octane-4,6-dione or A23 187 [ 13 1. This difference in 
efficiency coincides with a low affinity for Ca2+ of 
hypoglycemic sulfonylureas (Keq about lo-r4) 
[7,15] as compared to such ionophores as X537A 
(Keq = lo-“) and A23187 (Keq = 4.10-‘) [16,17]. 
In this perspective, it could be objected that the 
concentration of sulfonylurea used in the present 
experiments appears much higher than that used in 
studies performed with isolated pancreatic islets. 
Such is not the case, however, if reference is made 
to the concentration of drug/unit membrane area. 
In the present system, the amount of glibenclamide 
added to each sample (0.3-l.Opmol) relative to 
the area of the vesicles (about 3 m2, assuming a 
value of 4 mg phospholipid/m2 of bilayer) yielded 
a ratio of 0.10-0.33 pmol/m*. This is comparable 
to the situation found in islets incubated in the 
presence of 5- 16 PM glibenclamide (i.e., 
2.4-8.0 ,ug/ml). In this range of concentrations, 
the binding of glibenclamide to isolated islets in- 
creases from about 0.18-0.56 pmol/g dry weight 
[18]. Since the total area of plasma membrane in 
each islet (about 1.1 pg dry weight; see [19] is 
about 1.86 mm* [20], the binding of glibenclamide 
indeed corresponds to 0.10-0.33 pmol/m*. 
In conclusion, the present findings indicate that 
hypoglycemic sulfonylureas such as gliclazide and 
glibenclamide are able to transport Pr3+ across a 
lipid membrane. Since there is usually an analogy 
between the transport of Pr3+ and other cations, it 
is tempting to suggest, but remains to be proved, 
that hypoglycemic sulfonylureas may act in a com- 
parable manner in facilitating cation transport 
across the B-cell plasma membrane. 
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